首页 > 市场调查报告书 > 医疗设备

导管

市场调查报告书

商品编码

1606518

全球神经植入市场 - 2024-2031

Global Neurological Implants Market - 2024-2031

出版日期: 2024年12月04日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球神经植入市场达到58.8亿美元，预计2031年将达到123.9亿美元，2024-2031年预测期间复合年增长率为9.8%。

神经植入物是透过手术放置在大脑或神经系统内的医疗设备，具有多种功能。这些植入物可以刺激大脑的特定区域，以减轻与帕金森氏症、癫痫和慢性疼痛等神经系统疾病相关的症状。例如，深部脑部刺激（DBS）设备会向大脑的目标区域传送电脉衝，以帮助有效管理运动症状。

神经植入物可以与外部设备连接，使残疾人能够利用他们的思想控制义肢或其他辅助技术。这通常是透过脑机介面（BCI）来实现的，它将神经讯号转换为外部设备的命令。许多神经植入物在研究环境中用于研究大脑功能和神经系统疾病的潜在机制。透过记录神经活动，研究人员可以获得有关大脑运作的宝贵见解并开发新的治疗策略。

这些设备通常由一系列连接到特定大脑区域的电极以及处理从这些电极接收到的讯号的控制单元组成。电极可以透过发送电脉衝来刺激神经活动，也可以记录它以用于研究和治疗目的。这些因素推动了全球神经植入物市场的扩张。

市场动态：

驱动程式和限制

神经系统疾病的发生率上升

神经系统疾病发生率的上升极大地推动了全球神经植入物市场的成长，预计将在整个市场预测期内推动成长。

帕金森氏症、阿兹海默症、癫痫和慢性疼痛等神经系统疾病发生率的上升是推动全球神经植入物市场成长的主要因素。全球有数百万人受到这些疾病的影响，对有效治疗方案的需求不断增加，以改善患者的治疗效果并改善他们的生活品质。

《柳叶刀神经病学》发表的一项重要新研究表明，到2021 年，全球将有超过30 亿人患有神经系统疾病。、伤害负担的一部分，以及风险因素研究 (GBD) 2021资料。

神经系统疾病现已成为全世界健康不良和残疾的主要原因。自 1990 年以来，以神经系统疾病导致的残疾调整生命年 (DALY) 衡量的残疾、疾病和过早死亡的总体负担增加了 18%。

值得注意的是，超过 80% 与神经系统疾病相关的死亡和健康损失发生在低收入和中等收入国家。获得治疗的机会有明显差异；高收入国家每 10 万人中神经科专业人员的数量是低收入和中等收入国家的 70 倍。所有这些因素推动了全球神经植入物市场的发展。

神经植入物，包括深部脑部刺激（DBS）设备，已被证明可以透过向目标大脑区域传递电脉衝来有效缓解与运动障碍和癫痫相关的症状。对于使用传统药物治疗无效的患者来说，这些设备是一个有前景的选择。

此外，该行业的主要参与者推出产品并致力于创新研究，这将推动全球神经植入物市场的发展。例如，2024 年7 月，Mint Neurotechnologies Ltd (MintNeuro) 宣布启动「探索」项目，该项目得到了英国创新局透过2023 年生物医学催化剂可行性竞赛提供的10 万英镑资助。基础上再接再厉。延续先前的 DREAM 项目，并将 MintNeuro 的创新神经感测技术的应用范围扩展到其最初关注的抗药性癫痫之外。

此外，2024 年11 月，马斯克(Elon Musk) 的大脑植入公司Neuralink 宣布启动一项新的可行性研究，旨在测试其脑机介面(BCI) 植入物的新颖应用，使个人能够利用自己的思想控制机械手臂。这项进展在马斯克的社群媒体平台 X 上的一篇贴文中分享，Neuralink 对这项试验的批准和启动表示兴奋。此外，所有这些因素都对全球神经植入物市场提出了需求。

此外，对技术进步的需求不断增长有助于神经植入物市场的全球扩张。

设备和程序成本高昂

设备和手术的高成本将阻碍全球神经植入市场的成长。深部脑刺激器 (DBS) 等神经设备的植入涉及复杂的外科手术，需要专门的设备和训练有素的外科医生。

根据 HOSPIDIO 的说法。 2024 年的消息，印度的深部脑部刺激 (DBS) 手术对于寻求治疗帕金森氏症、特发性震颤和肌张力失调等疾病的患者来说是一个可行的选择。该手术的费用通常为 20,000 美元至 28,000 美元，约 16,50,000 卢比至 23,00,000 卢比。根据所使用的 DBS 设备的类型和品牌，成本可能会有很大差异。有些设备更先进或具有附加功能，这可能会增加整体费用。

这些手术的费用可能相当高，在美国等高收入国家通常为 35,000 美元至 100,000 美元。相比之下，在印度等国家，成本较低，通常在 15,000 美元至 30,000 美元之间。神经植入相关的高成本给医疗保健系统带来了相当大的经济压力，特别是在资源有限的地区。这种财务压力可能导致其他医疗需求的资金优先于神经系统治疗，从而限制了患有神经系统疾病的患者的可用性和可及性。因此，上述因素可能限制全球神经植入物市场的潜在成长。

Neurological implants are medical devices that are surgically placed within the brain or nervous system, serving a variety of functions. These implants can stimulate specific regions of the brain to alleviate symptoms associated with neurological disorders such as Parkinson's disease, epilepsy, and chronic pain. For instance, deep brain stimulation (DBS) devices deliver electrical impulses to targeted areas in the brain to help manage motor symptoms effectively.

Neurological implants can interface with external devices, enabling individuals with disabilities to control prosthetic limbs or other assistive technologies using their thoughts. This is often achieved through brain-computer interfaces (BCIs), which convert neural signals into commands for external devices. Many neurological implants are utilized in research environments to investigate brain function and the underlying mechanisms of neurological disorders. By recording neural activity, researchers can gain valuable insights into brain operations and develop new treatment strategies.

These devices typically consist of a series of electrodes that are attached to specific brain areas, along with a control unit that processes the signals received from these electrodes. The electrodes can either stimulate neural activity by sending electrical impulses or record it for research and therapeutic purposes. These factors have driven the global neurological implants market expansion.

Market Dynamics: Drivers & Restraints

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is significantly driving the growth of the global neurological implants market and is expected to drive throughout the market forecast period.

The rising incidence of neurological conditions such as Parkinson's disease, Alzheimer's disease, epilepsy, and chronic pain is a major factor driving the growth of the global neurological implants market. With millions of individuals affected by these disorders worldwide, there is an escalating demand for effective treatment options that can enhance patient outcomes and improve their quality of life.

A significant new study published in The Lancet Neurology reveals that over 3 billion people globally were living with a neurological condition in 2021. This analysis, which involved collaboration with the World Health Organization (WHO), is part of the Global Burden of Disease, Injuries, and Risk Factor Study (GBD) 2021 data.

Neurological conditions have now become the leading cause of ill health and disability worldwide. The overall burden of disability, illness, and premature death measured in terms of disability-adjusted life years (DALYs) attributable to neurological conditions has risen by 18% since 1990.

Notably, more than 80% of deaths and health loss associated with neurological disorders occur in low- and middle-income countries. There is a stark disparity in access to treatment; high-income countries have up to 70 times more neurological professionals per 100,000 people compared to their low- and middle-income counterparts. All these factors drive the global neurological implants market.

Neurological implants, including deep brain stimulation (DBS) devices, have proven effective in alleviating symptoms associated with movement disorders and epilepsy by delivering electrical impulses to targeted brain regions. These devices represent a promising option for patients who have not had success with traditional medications.

Furthermore, key players in the industry product launches and aiming for innovative studies that bwould drive this global neurological implants market. For instance, in July 2024, Mint Neurotechnologies Ltd (MintNeuro) announced the launch of the "EXPLORE" project, which is supported by a £100,000 grant from Innovate UK through the Biomedical Catalyst Feasibility Competition 2023. This initiative aims to build on the success of the previous DREAM project and expand the application of MintNeuro's innovative neural sensing technology beyond its initial focus on Drug-Resistant Epilepsy.

Also, in November 2024, Neuralink, Elon Musk's brain implant company, announced the launch of a new feasibility study aimed at testing its brain-computer interface (BCI) implant for a novel application enabling individuals to control a robotic arm using their thoughts. This development was shared in a post on Musk's social media platform, X, where Neuralink expressed excitement about the approval and initiation of this trial. Also, All these factors demand the global neurological implants market.

Moreover, the rising demand for technological advancements contributes to the global expansion of the neurological implants market.

High Costs of Devices and Procedures

The high costs of devices and procedures will hinder the growth of the global neurological implants market. The implantation of neurological devices, such as deep brain stimulators (DBS), involves intricate surgical procedures that necessitate specialized equipment and highly trained surgeons.

According to the HOSPIDIO. News in 2024, deep brain stimulation (DBS) surgery in India is a viable option for patients seeking treatment for conditions such as Parkinson's disease, essential tremor, and dystonia. The cost of this procedure typically ranges from $20,000 to $28,000, which is approximately ₹16,50,000 to ₹23,00,000. The cost can vary significantly depending on the type and brand of the DBS device used. Some devices are more advanced or come with additional features, which can increase the overall expense.

The costs for these surgeries can be quite significant, often ranging from USD 35,000 to USD 100,000 in high-income countries like the United States. In contrast, in countries like India, the costs are lower, typically between USD 15,000 and USD 30,000. The high costs associated with neurological implants place a considerable economic strain on healthcare systems, particularly in areas with limited resources. This financial pressure can lead to prioritization of funding for other medical needs over neurological treatments, thereby restricting availability and access for patients suffering from neurological disorders. Thus, the above factors could be limiting the global neurological implants market's potential growth.

Segment Analysis

The global neurological implants market is segmented based on product type, material, application, end-user, and region.

Product Type:

The deep brain stimulators segment is expected to dominate the global neurological implants market share

The deep brain stimulators segment holds a major portion of the global neurological implants market share and is expected to hold a significant portion of the global neurological implants market share during the forecast period.

Deep brain stimulation (DBS) involves the surgical implantation of electrodes into specific areas of the brain. These electrodes generate electrical impulses that modulate brain activity to treat various medical conditions. The electrical stimulation can also influence the cells and chemicals in the brain associated with these conditions.

The level of stimulation provided by DBS is regulated by a device similar to a pacemaker, which is implanted under the skin in the upper chest. A wire connects this device to the electrodes in the brain. DBS is an established treatment option for individuals with movement disorders, including essential tremor, Parkinson's disease, and dystonia.

Additionally, it is used for certain psychiatric conditions, such as obsessive-compulsive disorder (OCD), and has received approval from the Food and Drug Administration (FDA) for reducing seizures in patients with hard-to-treat epilepsy. DBS is typically recommended for patients whose symptoms are not adequately managed through medication alone.

Furthermore, key players in the industry research studies and product launches & approvals that would drive this segment growth in the global neurological implants market. For instance, in January 2024, researchers at the University of California San Diego developed an innovative neural implant that can capture information about brain activity from deep within the brain while resting on its surface. This breakthrough is made possible by a thin, transparent, and flexible polymer strip embedded with a dense array of graphene electrodes.

The technology represents a significant advancement toward creating a minimally invasive brain-computer interface (BCI) that can provide high-resolution data regarding deep neural activity through recordings taken from the brain's surface.

Also, in January 2024, Abbott announced that it had received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC deep brain stimulation (DBS) system. This device is notable for being the world's smallest rechargeable DBS system equipped with remote programming capabilities, specifically designed to treat individuals with movement disorders such as Parkinson's disease and essential tremor. These factors have solidified the segment's position in the global neurological implants market.

Geographical Analysis

North America is expected to hold a significant position in the global neurological implants market share

North America holds a substantial position in the global neurological implants market and is expected to hold most of the market share.

The prevalence of neurological disorders is steadily increasing due to various factors, including an aging population and lifestyle changes. For instance, as per Alzheimer's Disease Facts and Figures data in February 2021, the number of individuals living with Alzheimer's dementia in the United States is expected to rise from approximately 5.8 million in 2021 to 14.3 million by 2060, underscoring the urgent need for effective therapies to manage these conditions. Similarly, over 1 million Americans are diagnosed with Parkinson's disease, while around 5.1 million live with epilepsy.

Similarly, the incidence of neurological conditions such as Parkinson's disease, Alzheimer's disease, epilepsy, and chronic pain is steadily increasing. As per NCBI data in April 2022, In the U.S., millions are affected, leading to heightened demand for effective treatment options. For instance, approximately 6.5 million Americans aged 65 and older are living with Alzheimer's dementia as of 2022.

Deep brain stimulation (DBS) system equipped with sensing capabilities available on the market. This technology enables physicians to customize treatment for patients suffering from movement disorders, including Parkinson's disease, essential tremor, dystonia, and even epilepsy. In the United States, over 11 million individuals are affected by movement disorders, while approximately 3.4 million people live with epilepsy.

Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, technological advancements, & investments and product launches & approvals would propel the global neurological implants market growth. For instance, in November 2024, Neuralink received authorization from Health Canada to commence clinical trials in Canada for its brain chip technology. This approval marks a significant step for the company as it expands its research efforts beyond the United States. Neuralink is now actively seeking volunteers to participate in these trials, which aim to evaluate the safety and effectiveness of its brain-computer interface (BCI) technology.

Also, in October 2022, Axoft officially launched its brain-machine interface (BMI) technology and announced that it has received the FDA Breakthrough Device designation. This designation is intended to expedite the development and review process for devices that have the potential to provide significant benefits to patients with serious conditions. The company has successfully secured $8 million in funding to support pre-clinical studies with the FDA and to scale up prototypes of its innovative neural implants, which are designed to be "as soft as the brain."

Thus, the above factors are consolidating the region's position as a dominant force in the global neurological implants market.

Asia Pacific is growing at the fastest pace in the global neurological implants market

Asia Pacific holds the fastest pace in the global neurological implants market and is expected to hold most of the market share.

The region is seeing a significant rise in neurodegenerative and psychiatric conditions, such as Parkinson's disease, Alzheimer's disease, and epilepsy. This growing incidence creates an urgent demand for effective treatment options, thereby boosting the need for neurological implants.

The aging population in Asia Pacific countries significantly contributes to the prevalence of neurological disorders, as older adults are more susceptible to these conditions. This demographic shift increases the demand for effective treatment options, including neurological implants.

According to The Lancet Regional Health - Western Pacific research data in 2021, China reported the highest age-standardized incidence and prevalence rates of Parkinson's disease (PD) among the G20 countries, with figures of 24.3 per 100,000 for incidence and 245.7 per 100,000 for prevalence. These rates significantly exceed the global averages. From 1990 to 2021, the age-standardized incidence of PD in China rose by 89.7%, while the age-standardized prevalence increased by 167.8%, marking the largest increase observed among the G20 nations. Thus, all these factors demand the neurological implant market.

The introduction of advanced technologies, such as MRI-safe brain implants, brain-computer interfaces (BCIs), and other innovative devices, enhances the treatment options available in the region. These advancements improve patient outcomes and encourage adoption among healthcare providers.

Furthermore, key players in the region more focus on research studies and product launches that would drive the neurological implant market. For instance, according to the NIPS data in April 2022, researchers from the University of South Alabama College of Medicine and the National Institute for Physiological Sciences in Japan have developed a novel method of deep brain stimulation (DBS) that is driven by motor cortical activity. This innovative approach has shown effectiveness in treating motor symptoms in monkeys with Parkinson's disease.

Also, in April 2024, Medtronic launched the NeuroSmart Portable MER Navigation System in India, specifically designed for deep brain stimulation (DBS) therapy in patients with Parkinson's disease. This advanced technology aims to enhance the precision and effectiveness of DBS procedures, which are used to alleviate motor symptoms associated with Parkinson's disease.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global neurological implants market.

Competitive Landscape

The major global players in the neurological implants market include Medtronic, Boston Scientific Corporation, NeuroPace Inc., Abbott Laboratories, Aleva Neurotherapeutics, Renishaw PLC, NEVRO CORP., Synapse Biomedical Inc., and LivaNova PLC among others.

Key Developments

In January 2024, Medtronic plc announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Percept RC Deep Brain Stimulation (DBS) system. This rechargeable neurostimulator is the latest addition to the Medtronic Percept family, which also includes the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurological implants market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Incidence of Neurological Disorders
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Devices and Procedures
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Deep Brain Stimulators*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Vagus Nerve Stimulators
6.4. Spinal Cord Stimulators

7. By Material

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 7.1.2. Market Attractiveness Index, By Material
7.2. Silicon*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Tungsten
7.4. Platinum-iridium
7.5. Nanotubes
7.6. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Chronic Pain*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parkinson's Disease
8.4. Epilepsy
8.5. Depression
8.6. Essential Tremor
8.7. Alzheimer's Disease

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Neurology Clinics
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Medtronic*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Boston Scientific Corporation
12.3. NeuroPace Inc.
12.4. Abbott Laboratories
12.5. Aleva Neurotherapeutics
12.6. Renishaw PLC
12.7. NEVRO CORP.
12.8. Synapse Biomedical Inc.
12.9. LivaNova PLC

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球神经植入市场 - 2024-2031

Global Neurological Implants Market - 2024-2031

市场动态：

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

第 5 章：产业分析

第 6 章：依产品类型

第 7 章：按材料

第 8 章：按申请

第 9 章：最终用户

第 10 章：按地区

第 11 章：竞争格局

第 12 章：公司简介

第 13 章：附录